Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
49
SRPT Quote, Financials, Valuation and Earnings
Last price:
$23.83
Seasonality move
:
4.67%
Day range:
$23.05 - $23.89
52-week range:
$10.42 - $128.75
Dividend yield:
0%
P/E ratio:
20.50x
P/S ratio:
0.99x
P/B ratio:
1.84x
Volume:
3.1M
Avg. volume:
2.9M
1-year change:
-81.67%
Market cap:
$2.4B
Revenue:
$1.9B
EPS (TTM):
-$2.89
Analysts' Opinion
-
Consensus RatingSarepta Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 14 Hold ratings, and 3 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $20.70, Sarepta Therapeutics, Inc. has an estimated downside of -10.6% from its current price of $23.15.
-
Price Target UpsideAccording to analysts, the highest upside price target is $45.00 representing 94.38% upside increase from its current price of $23.15.
Fair Value
-
According to the consensus of 24 analysts, Sarepta Therapeutics, Inc. has -10.6% downside to fair value with a price target of $20.70 per share.
SRPT vs. S&P 500
-
Over the past 5 trading days, Sarepta Therapeutics, Inc. has overperformed the S&P 500 by 6.6% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sarepta Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sarepta Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Sarepta Therapeutics, Inc. reported revenues of $399.4M.
Earnings Growth
-
Sarepta Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Sarepta Therapeutics, Inc. reported earnings per share of -$1.80.
Enterprise value:
2.8B
EV / Invested capital:
--
Price / LTM sales:
0.99x
EV / EBIT:
15.47x
EV / Revenue:
1.17x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
39.98x
Gross Profit (TTM):
$1.8B
Return On Assets:
-7.46%
Net Income Margin (TTM):
-11.25%
Return On Equity:
-20.67%
Return On Invested Capital:
-10.24%
Operating Margin:
-15.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.6B | $2.4B | $467.2M | $399.4M | |
| Gross Profit | $924.4M | $1.4B | $1.8B | $365.7M | $230.1M | |
| Operating Income | -$399.3M | $81M | -$86M | $22.2M | -$62.9M | |
| EBITDA | -$341.5M | $135.8M | -$21.1M | $36.3M | -$41.1M | |
| Diluted EPS | -$7.83 | $1.20 | -$2.89 | $0.34 | -$1.80 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2B | $2.6B | $2.5B | $2.7B | $2.7B | |
| Total Assets | $2.7B | $3.2B | $3.1B | $3.6B | $3.5B | |
| Current Liabilities | $373.4M | $602.9M | $450.7M | $699.5M | $921.4M | |
| Total Liabilities | $2.2B | $2.7B | $2.3B | $2.4B | $2.2B | |
| Total Equity | $469.5M | $430.8M | $764.4M | $1.2B | $1.3B | |
| Total Debt | $1.2B | $1.6B | $1.4B | $1.4B | $1.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$538.7M | -$352.5M | -$257.4M | -$70.7M | -$27.4M | |
| Cash From Investing | -$91.6M | -$72.9M | $737.6M | -$128.8M | $232.4M | |
| Cash From Financing | $133.8M | $77.8M | -$67.4M | $13.8M | -$105M | |
| Free Cash Flow | -$615M | -$480.4M | -$401.6M | -$108M | -$55.6M | |
SRPT
Sector
Market Cap
$2.4B
$28.3M
Price % of 52-Week High
17.98%
51.99%
Dividend Yield
0%
0%
Shareholder Yield
0.45%
-1.59%
1-Year Price Total Return
-81.67%
-17.41%
Beta (5-Year)
0.485
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$22.02
200-day SMA
Sell
Level
$27.99
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$21.79
Relative Strength Index (RSI14)
Buy
Level
63.80
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-24.3719
50-day SMA
Buy
Level
$20.65
MACD (12, 26)
Buy
Level
0.49
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
--
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.7857)
Sell
CA Score
(Annual)
Level (-0.7661)
Sell
Beneish M-Score
(Annual)
Level (-1.4663)
Sell
Momentum Score
Level (1)
Buy
Ohlson Score
Level (-2.133)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, SRPT has received 7 Buy ratings 14 Hold ratings, and 3 Sell ratings. The SRPT average analyst price target in the past 3 months is $20.70.
-
Where Will Sarepta Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sarepta Therapeutics, Inc. share price will drop to $20.70 per share over the next 12 months.
-
What Do Analysts Say About Sarepta Therapeutics, Inc.?
Analysts are divided on their view about Sarepta Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sarepta Therapeutics, Inc. is a Sell and believe this share price will rise from its current level to $5.00.
-
What Is Sarepta Therapeutics, Inc.'s Price Target?
The price target for Sarepta Therapeutics, Inc. over the next 1-year time period is forecast to be $20.70 according to 24 Wall Street analysts, 7 of them rate the stock a Buy, 3 rate the stock a Sell, and 14 analysts rate the stock a Hold.
-
Is SRPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sarepta Therapeutics, Inc. is a Hold. 14 of 24 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of SRPT?
You can purchase shares of Sarepta Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sarepta Therapeutics, Inc. shares.
-
What Is The Sarepta Therapeutics, Inc. Share Price Today?
Sarepta Therapeutics, Inc. was last trading at $23.83 per share. This represents the most recent stock quote for Sarepta Therapeutics, Inc.. Yesterday, Sarepta Therapeutics, Inc. closed at $23.15 per share.
-
How To Buy Sarepta Therapeutics, Inc. Stock Online?
In order to purchase Sarepta Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SRPT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SRPT
Sector
P/E ratio
20.50x
24.24x
PEG ratio
--
-0.01x
P/B ratio
1.84x
1.84x
Price / LTM sales
0.99x
1.60x
Growth Metrics
SRPT
Sector
Revenue growth
-14.52%
4.6%
Earnings growth
-630.03%
10.71%
Revenue (5-year growth)
37.94%
6.45%
Earnings forecast
-$0.70
-$0.19
Profitability
SRPT
Sector
Profitability FY 2024
$1.5B
$3.5M
Return on invested capital
-10.24%
-32.04%
Return on assets
-7.46%
-28.44%
Return on equity
-20.67%
-38.09%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
2
Balance Sheet
SRPT
Sector
Total cash
$851M
$26.1M
Short term investments
$251.8M
$25.7M
Total assets
$4B
$76.4M
Long term debt
$1.3B
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
